{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:13:05Z","timestamp":1794557585334,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Stichting Alzheimer Onderzoek, BE","award":["2021\/0012"],"award-info":[{"award-number":["2021\/0012"]}]},{"name":"Stichting Alzheimer Onderzoek, BE","award":["2022\/022"],"award-info":[{"award-number":["2022\/022"]}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G008023N"],"award-info":[{"award-number":["G008023N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["G0C4220N"],"award-info":[{"award-number":["G0C4220N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["SB 1S59621N"],"award-info":[{"award-number":["SB 1S59621N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","award":["--"],"award-info":[{"award-number":["--"]}],"id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UK NIHR UCLH Biomedical Research Centre","award":["--"],"award-info":[{"award-number":["--"]}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["--"],"award-info":[{"award-number":["--"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Autosomal Dominant Alzheimer's Disease (ADAD), caused by mutations in Presenilins (\n                      <jats:italic>PSEN1\/2<\/jats:italic>\n                      ) and Amyloid Precursor Protein (\n                      <jats:italic>APP<\/jats:italic>\n                      ) genes, typically manifests with early onset (&lt; 65 years). Age at\u00a0symptom onset (AAO) is relatively consistent among carriers of the same\n                      <jats:italic>PSEN1<\/jats:italic>\n                      mutation, but more variable for\n                      <jats:italic>PSEN2<\/jats:italic>\n                      and\n                      <jats:italic>APP<\/jats:italic>\n                      variants, with these mutations associated with later AAOs than\n                      <jats:italic>PSEN1<\/jats:italic>\n                      . Understanding this clinical variability is crucial for understanding disease mechanisms, developing predictive models and tailored interventions in ADAD, with potential implications for sporadic AD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed biochemical assessment of \u03b3-secretase dysfunction on 28 PSEN2 and 19 APP mutations, including disease-associated, unclear and benign variants. This analysis has been valuable in the assessment of\n                      <jats:italic>PSEN1<\/jats:italic>\n                      variant pathogenicity, disease onset and progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our analysis reveals linear correlations between the molecular composition of A\u03b2 profiles and AAO for both\n                      <jats:italic>PSEN2<\/jats:italic>\n                      (R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009= 0.52) and\n                      <jats:italic>APP<\/jats:italic>\n                      (R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009= 0.69) mutations. The integration of PSEN1, PSEN2 and APP correlation data shows parallel but shifted lines, suggesting a common pathogenic mechanism with gene-specific shifts in onset. We found overall \u201cdelays\u201d in AAOs of 27 years for PSEN2 and 8\u00a0years for APP variants, compared to PSEN1. Notably, extremely inactivating\n                      <jats:italic>PSEN1<\/jats:italic>\n                      variants delayed onset, suggesting that reduced contribution to brain APP processing underlies the later onset of PSEN2 variants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study supports a unified model of ADAD pathogenesis wherein \u03b3-secretase dysfunction and the resulting shifts in A\u03b2 profiles are central to disease onset across all causal genes. While similar shifts in A\u03b2 occur across causal genes, their impact on AAO varies in the function of their contribution to APP processing in the brain. This biochemical analysis establishes quantitative relationships that enable predictive AAO modelling with implications for clinical practice and genetic research. Our findings also support the development of therapeutic strategies modulating \u03b3-secretase across different genetic ADAD forms and potentially more broadly in AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13024-025-00832-1","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T22:28:40Z","timestamp":1745620120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Spectrum of \u03b3-Secretase dysfunction as a unifying predictor of ADAD age at onset across PSEN1, PSEN2 and APP causal genes"],"prefix":"10.1186","volume":"20","author":[{"given":"Sara Guti\u00e9rrez","family":"Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Gan","family":"Oria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Annaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Ringman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick C.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Ch\u00e1vez-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"832_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer\u2019s disease. Lancet. 2021;397:1577\u201390.","journal-title":"Lancet"},{"key":"832_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semcdb.2020.03.005","volume":"105","author":"L Chavez-Gutierrez","year":"2020","unstructured":"Chavez-Gutierrez L, Szaruga M. Mechanisms of neurodegeneration - Insights from familial Alzheimer\u2019s disease. Semin Cell Dev Biol. 2020;105:75\u201385.","journal-title":"Semin Cell Dev Biol"},{"key":"832_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1212\/WNL.0000000000000596","volume":"83","author":"DC Ryman","year":"2014","unstructured":"Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83:253\u201360.","journal-title":"Neurology"},{"key":"832_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt59","volume":"3","author":"RJ Bateman","year":"2011","unstructured":"Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer\u2019s disease: a review and proposal for the prevention of Alzheimer\u2019s disease. Alzheimers Res Ther. 2011;3:1.","journal-title":"Alzheimers Res Ther"},{"key":"832_CR5","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1074\/jbc.M113.530907","volume":"289","author":"H Acx","year":"2014","unstructured":"Acx H, Chavez-Gutierrez L, Serneels L, Lismont S, Benurwar M, Elad N, De Strooper B. Signature amyloid beta profiles are produced by different gamma-secretase complexes. J Biol Chem. 2014;289:4346\u201355.","journal-title":"J Biol Chem"},{"key":"832_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.cell.2016.05.020","volume":"166","author":"R Sannerud","year":"2016","unstructured":"Sannerud R, Esselens C, Ejsmont P, Mattera R, Rochin L, Tharkeshwar AK, De Baets G, De Wever V, Habets R, Baert V, et al. Restricted Location of PSEN2\/gamma-Secretase Determines Substrate Specificity and Generates an Intracellular Abeta Pool. Cell. 2016;166:193\u2013208.","journal-title":"Cell"},{"key":"832_CR7","doi-asserted-by":"publisher","first-page":"13042","DOI":"10.1523\/JNEUROSCI.2362-09.2009","volume":"29","author":"M Takami","year":"2009","unstructured":"Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci. 2009;29:13042\u201352.","journal-title":"J Neurosci"},{"key":"832_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.286.5440.735","volume":"286","author":"R Vassar","year":"1999","unstructured":"Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al. Beta-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735\u201341.","journal-title":"Science"},{"key":"832_CR9","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1038\/emboj.2012.79","volume":"31","author":"L Chavez-Gutierrez","year":"2012","unstructured":"Chavez-Gutierrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, Lismont S, Zhou L, Van Cleynenbreugel S, Esselmann H, et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261\u201374.","journal-title":"EMBO J"},{"key":"832_CR10","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1084\/jem.20150892","volume":"212","author":"M Szaruga","year":"2015","unstructured":"Szaruga M, Veugelen S, Benurwar M, Lismont S, Sepulveda-Falla D, Lleo A, Ryan NS, Lashley T, Fox NC, Murayama S, et al. Qualitative changes in human gamma-secretase underlie familial Alzheimer\u2019s disease. J Exp Med. 2015;212:2003\u201313.","journal-title":"J Exp Med"},{"issue":"443\u2013456","key":"832_CR11","first-page":"e414","volume":"170","author":"M Szaruga","year":"2017","unstructured":"Szaruga M, Munteanu B, Lismont S, Veugelen S, Horre K, Mercken M, Saido TC, Ryan NS, De Vos T, Savvides SN, et al. Alzheimer\u2019s-Causing Mutations Shift Abeta Length by Destabilizing gamma-Secretase-Abetan Interactions. Cell. 2017;170(443\u2013456): e414.","journal-title":"Cell"},{"key":"832_CR12","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/383710a0","volume":"383","author":"K Duff","year":"1996","unstructured":"Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 1996;383:710\u20133.","journal-title":"Nature"},{"key":"832_CR13","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0896-6273(00)80230-5","volume":"17","author":"DR Borchelt","year":"1996","unstructured":"Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, et al. Familial Alzheimer\u2019s disease-linked presenilin 1 variants elevate Abeta1-42\/1-40 ratio in vitro and in vivo. Neuron. 1996;17:1005\u201313.","journal-title":"Neuron"},{"key":"832_CR14","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med. 1996;2:864\u201370.","journal-title":"Nat Med"},{"key":"832_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nm0197-67","volume":"3","author":"M Citron","year":"1997","unstructured":"Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, et al. Mutant presenilins of Alzheimer\u2019s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med. 1997;3:67\u201372.","journal-title":"Nat Med"},{"key":"832_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0304-3940(99)00187-1","volume":"265","author":"O Murayama","year":"1999","unstructured":"Murayama O, Tomita T, Nihonmatsu N, Murayama M, Sun X, Honda T, Iwatsubo T, Takashima A. Enhancement of amyloid beta 42 secretion by 28 different presenilin 1 mutations of familial Alzheimer\u2019s disease. Neurosci Lett. 1999;265:61\u20133.","journal-title":"Neurosci Lett"},{"key":"832_CR17","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.neuron.2016.03.010","volume":"90","author":"S Veugelen","year":"2016","unstructured":"Veugelen S, Saito T, Saido TC, Chavez-Gutierrez L, De Strooper B. Familial Alzheimer\u2019s Disease Mutations in Presenilin Generate Amyloidogenic Abeta Peptide Seeds. Neuron. 2016;90:410\u20136.","journal-title":"Neuron"},{"key":"832_CR18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nn.2858","volume":"14","author":"T Saito","year":"2011","unstructured":"Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, Matsuba Y, Yamada K, Nilsson P, Takano J, et al. Potent amyloidogenicity and pathogenicity of Abeta43. Nat Neurosci. 2011;14:1023\u201332.","journal-title":"Nat Neurosci"},{"key":"832_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.15252\/emmm.201505952","volume":"8","author":"B Kretner","year":"2016","unstructured":"Kretner B, Trambauer J, Fukumori A, Mielke J, Kuhn PH, Kremmer E, Giese A, Lichtenthaler SF, Haass C, Arzberger T, Steiner H. Generation and deposition of Abeta43 by the virtually inactive presenilin-1 L435F mutant contradicts the presenilin loss-of-function hypothesis of Alzheimer\u2019s disease. EMBO Mol Med. 2016;8:458\u201365.","journal-title":"EMBO Mol Med"},{"key":"832_CR20","doi-asserted-by":"publisher","first-page":"7084","DOI":"10.1038\/s41467-022-34742-3","volume":"13","author":"M Seuma","year":"2022","unstructured":"Seuma M, Lehner B, Bolognesi B. An atlas of amyloid aggregation: the impact of substitutions, insertions, deletions and truncations on amyloid beta fibril nucleation. Nat Commun. 2022;13:7084.","journal-title":"Nat Commun"},{"key":"832_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid beta-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther. 2023;8:248.","journal-title":"Signal Transduct Target Ther"},{"key":"832_CR22","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","volume":"186","author":"M Jucker","year":"2023","unstructured":"Jucker M, Walker LC. Alzheimer\u2019s disease: From immunotherapy to immunoprevention. Cell. 2023;186:4260\u201370.","journal-title":"Cell"},{"key":"832_CR23","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1038\/s41380-022-01518-6","volume":"27","author":"D Petit","year":"2022","unstructured":"Petit D, Fernandez SG, Zoltowska KM, Enzlein T, Ryan NS, O\u2019Connor A, Szaruga M, Hill E, Vandenberghe R, Fox NC, Chavez-Gutierrez L. Abeta profiles generated by Alzheimer\u2019s disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Mol Psychiatry. 2022;27:2821\u201332.","journal-title":"Mol Psychiatry"},{"key":"832_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1474-4422(24)00236-9","volume":"23","author":"SA Schultz","year":"2024","unstructured":"Schultz SA, Liu L, Schultz AP, Fitzpatrick CD, Levin R, Bellier JP, Shirzadi Z, Joseph-Mathurin N, Chen CD, Benzinger TLS, et al. gamma-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer\u2019s disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol. 2024;23:913\u201324.","journal-title":"Lancet Neurol"},{"key":"832_CR25","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/S1474-4422(16)30193-4","volume":"15","author":"NS Ryan","year":"2016","unstructured":"Ryan NS, Nicholas JM, Weston PSJ, Liang Y, Lashley T, Guerreiro R, Adamson G, Kenny J, Beck J, Chavez-Gutierrez L, et al. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer\u2019s disease: a case series. Lancet Neurol. 2016;15:1326\u201335.","journal-title":"Lancet Neurol"},{"key":"832_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jpsychires.2019.03.026","volume":"113","author":"G Wang","year":"2019","unstructured":"Wang G, Zhang DF, Jiang HY, Fan Y, Ma L, Shen Z, Bi R, Xu M, Tan L, Shan B, et al. Mutation and association analyses of dementia-causal genes in Han Chinese patients with early-onset and familial Alzheimer\u2019s disease. J Psychiatr Res. 2019;113:141\u20137.","journal-title":"J Psychiatr Res"},{"key":"832_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/alz.12005","volume":"16","author":"L Jia","year":"2020","unstructured":"Jia L, Fu Y, Shen L, Zhang H, Zhu M, Qiu Q, Wang Q, Yan X, Kong C, Hao J, et al. PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer\u2019s disease. Alzheimers Dement. 2020;16:178\u201391.","journal-title":"Alzheimers Dement"},{"key":"832_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2174\/1567205018666210608120339","volume":"18","author":"C Mao","year":"2021","unstructured":"Mao C, Li J, Dong L, Huang X, Lei D, Wang J, Chu S, Liu C, Peng B, Roman GC, et al. Clinical Phenotype and Mutation Spectrum of Alzheimer\u2019s Disease with Causative Genetic Mutation in a Chinese Cohort. Curr Alzheimer Res. 2021;18:265\u201372.","journal-title":"Curr Alzheimer Res"},{"key":"832_CR29","doi-asserted-by":"publisher","first-page":"D835","DOI":"10.1093\/nar\/gkz972","volume":"48","author":"MJ Landrum","year":"2020","unstructured":"Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu B, Hart J, Hoffman D, Jang W, Kaur K, Liu C, et al. ClinVar: improvements to accessing data. Nucleic Acids Res. 2020;48:D835\u201344.","journal-title":"Nucleic Acids Res"},{"key":"832_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/alz.12646","volume":"19","author":"L Liu","year":"2023","unstructured":"Liu L, Lauro BM, He A, Lee H, Bhattarai S, Wolfe MS, Bennett DA, Karch CM, Young-Pearse T. Dominantly Inherited Alzheimer N, Selkoe DJ: Identification of the Abeta37\/42 peptide ratio in CSF as an improved Abeta biomarker for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:79\u201396.","journal-title":"Alzheimers Dement"},{"key":"832_CR31","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.7638622","volume":"269","author":"E Levy-Lahad","year":"1995","unstructured":"Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al. Candidate gene for the chromosome 1 familial Alzheimer\u2019s disease locus. Science. 1995;269:973\u20137.","journal-title":"Science"},{"key":"832_CR32","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ana.20571","volume":"58","author":"L Obici","year":"2005","unstructured":"Obici L, Demarchi A, de Rosa G, Bellotti V, Marciano S, Donadei S, Arbustini E, Palladini G, Diegoli M, Genovese E, et al. A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann Neurol. 2005;58:639\u201344.","journal-title":"Ann Neurol"},{"key":"832_CR33","doi-asserted-by":"crossref","unstructured":"Bolduc DM, Montagna DR, Seghers MC, Wolfe MS, Selkoe DJ: The amyloid-beta forming tripeptide cleavage mechanism of gamma-secretase. Elife 2016, 5.","DOI":"10.7554\/eLife.17578"},{"key":"832_CR34","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1038\/ncomms3246","volume":"4","author":"M Dimitrov","year":"2013","unstructured":"Dimitrov M, Alattia JR, Lemmin T, Lehal R, Fligier A, Houacine J, Hussain I, Radtke F, Dal Peraro M, Beher D, Fraering PC. Alzheimer\u2019s disease mutations in APP but not gamma-secretase modulators affect epsilon-cleavage-dependent AICD production. Nat Commun. 2013;4:2246.","journal-title":"Nat Commun"},{"key":"832_CR35","doi-asserted-by":"publisher","first-page":"8867","DOI":"10.1002\/alz.14339","volume":"20","author":"L Liu","year":"2024","unstructured":"Liu L, Schultz SA, Saba A, Yang HS, Li A, Selkoe DJ, Chhatwal JP. The pathogenicity of PSEN2 variants is tied to Abeta production and homology to PSEN1. Alzheimers Dement. 2024;20:8867\u201377.","journal-title":"Alzheimers Dement"},{"key":"832_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s40478-023-01694-8","volume":"11","author":"Y Yang","year":"2023","unstructured":"Yang Y, Murzin AG, Peak-Chew S, Franco C, Garringer HJ, Newell KL, Ghetti B, Goedert M, Scheres SHW. Cryo-EM structures of Abeta40 filaments from the leptomeninges of individuals with Alzheimer\u2019s disease and cerebral amyloid angiopathy. Acta Neuropathol Commun. 2023;11:191.","journal-title":"Acta Neuropathol Commun"},{"key":"832_CR37","doi-asserted-by":"publisher","first-page":"e1007045","DOI":"10.1371\/journal.pgen.1007045","volume":"13","author":"MV Fernandez","year":"2017","unstructured":"Fernandez MV, Kim JH, Budde JP, Black K, Medvedeva A, Saef B, Deming Y, Del-Aguila J, Ibanez L, Dube U, et al. Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. PLoS Genet. 2017;13: e1007045.","journal-title":"PLoS Genet"},{"key":"832_CR38","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1038\/s41380-018-0224-0","volume":"25","author":"C Koriath","year":"2020","unstructured":"Koriath C, Kenny J, Adamson G, Druyeh R, Taylor W, Beck J, Quinn L, Mok TH, Dimitriadis A, Norsworthy P, et al. Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. Mol Psychiatry. 2020;25:3399\u2013412.","journal-title":"Mol Psychiatry"},{"key":"832_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ng1292-255","volume":"2","author":"DA Carter","year":"1992","unstructured":"Carter DA, Desmarais E, Bellis M, Campion D, Clerget-Darpoux F, Brice A, Agid Y, Jaillard-Serradt A, Mallet J. More missense in amyloid gene. Nat Genet. 1992;2:255\u20136.","journal-title":"Nat Genet"},{"key":"832_CR40","doi-asserted-by":"crossref","unstructured":"Wang D, Scalici A, Wang Y, Lin H, Pitsillides A, Heard-Costa N, Cruchaga C, Ziegemeier E, Bis JC, Fornage M, et al: Frequency of Variants in Mendelian Alzheimer's Disease Genes within the Alzheimer's Disease Sequencing Project (ADSP). medRxiv 2024.","DOI":"10.1101\/2023.10.24.23297227"},{"key":"832_CR41","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3109\/00207454.2014.952730","volume":"125","author":"G Wu","year":"2015","unstructured":"Wu G, Wu Z, Na S, Hershey JC. Quantitative assessment of Abeta peptide in brain, cerebrospinal fluid and plasma following oral administration of gamma-secretase inhibitor MRK-560 in rats. Int J Neurosci. 2015;125:616\u201324.","journal-title":"Int J Neurosci"},{"key":"832_CR42","doi-asserted-by":"publisher","first-page":"10412","DOI":"10.1038\/s41467-024-54777-y","volume":"15","author":"A Perdok","year":"2024","unstructured":"Perdok A, Van Acker ZP, Vrancx C, Sannerud R, Vorsters I, Verrengia A, Callaerts-Vegh Z, Creemers E, Gutierrez Fernandez S, D\u2019Hauw B, et al. Altered expression of Presenilin2 impacts endolysosomal homeostasis and synapse function in Alzheimer\u2019s disease-relevant brain circuits. Nat Commun. 2024;15:10412.","journal-title":"Nat Commun"},{"key":"832_CR43","doi-asserted-by":"crossref","unstructured":"Lalli MA, Cox HC, Arcila ML, Cadavid L, Moreno S, Garcia G, Madrigal L, Reiman EM, Arcos-Burgos M, Bedoya G, et al: Origin of the PSEN1 E280A mutation causing early-onset Alzheimer's disease. Alzheimers Dement. 2014;10:S277-S283 e210.","DOI":"10.1016\/j.jalz.2013.09.005"},{"key":"832_CR44","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","volume":"25","author":"JF Arboleda-Velasquez","year":"2019","unstructured":"Arboleda-Velasquez JF, Lopera F, O\u2019Hare M, Delgado-Tirado S, Marino C, Chmielewska N, Saez-Torres KL, Amarnani D, Schultz AP, Sperling RA, et al. Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680\u20133.","journal-title":"Nat Med"},{"key":"832_CR45","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41591-023-02318-3","volume":"29","author":"F Lopera","year":"2023","unstructured":"Lopera F, Marino C, Chandrahas AS, O\u2019Hare M, Villalba-Moreno ND, Aguillon D, Baena A, Sanchez JS, Vila-Castelar C, Ramirez Gomez L, et al. Resilience to autosomal dominant Alzheimer\u2019s disease in a Reelin-COLBOS heterozygous man. Nat Med. 2023;29:1243\u201352.","journal-title":"Nat Med"},{"key":"832_CR46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/brain\/awac294","volume":"146","author":"MM Course","year":"2023","unstructured":"Course MM, Gudsnuk K, Keene CD, Bird TD, Jayadev S, Valdmanis PN. Aberrant splicing of PSEN2, but not PSEN1, in individuals with sporadic Alzheimer\u2019s disease. Brain. 2023;146:507\u201318.","journal-title":"Brain"},{"key":"832_CR47","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-018-0718-6","volume":"563","author":"MH Lee","year":"2018","unstructured":"Lee MH, Siddoway B, Kaeser GE, Segota I, Rivera R, Romanow WJ, Liu CS, Park C, Kennedy G, Long T, Chun J. Somatic APP gene recombination in Alzheimer\u2019s disease and normal neurons. Nature. 2018;563:639\u201345.","journal-title":"Nature"},{"key":"832_CR48","doi-asserted-by":"crossref","unstructured":"Bushman DM, Kaeser GE, Siddoway B, Westra JW, Rivera RR, Rehen SK, Yung YC, Chun J: Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer's disease brains. Elife 2015, 4.","DOI":"10.7554\/eLife.05116"},{"key":"832_CR49","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s44318-024-00057-w","volume":"43","author":"B De Strooper","year":"2024","unstructured":"De Strooper B, Karran E. New precision medicine avenues to the prevention of Alzheimer\u2019s disease from insights into the structure and function of gamma-secretases. EMBO J. 2024;43:887\u2013903.","journal-title":"EMBO J"},{"key":"832_CR50","doi-asserted-by":"publisher","first-page":"e111084","DOI":"10.15252\/embj.2022111084","volume":"41","author":"D Petit","year":"2022","unstructured":"Petit D, Hitzenberger M, Koch M, Lismont S, Zoltowska KM, Enzlein T, Hopf C, Zacharias M, Chavez-Gutierrez L. Enzyme-substrate interface targeting by imidazole-based gamma-secretase modulators activates gamma-secretase and stabilizes its interaction with APP. EMBO J. 2022;41: e111084.","journal-title":"EMBO J"},{"key":"832_CR51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13578-021-00738-7","volume":"12","author":"JE Luo","year":"2022","unstructured":"Luo JE, Li YM. Turning the tide on Alzheimer\u2019s disease: modulation of gamma-secretase. Cell Biosci. 2022;12:2.","journal-title":"Cell Biosci"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00832-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T11:02:48Z","timestamp":1745665368000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-025-00832-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00832-1","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SGF, CGO, WA, JMR and NSR declare no competing interests. NCF reports consultancy for Roche, Biogen and Ionis and serving on a Data Safety Monitoring Board for Biogen. LGC reports consultancy for Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}